Spots Global Cancer Trial Database for newly diagnosed multiple myeloma
Every month we try and update this database with for newly diagnosed multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | NCT04091126 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM) | NCT05276622 | Multiple Myelom... | Comprehensive G... Qualitative pat... Surveys on well... | 55 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | NCT04196491 | Multiple Myelom... | bb2121 Fludarabine Cyclophosphamid... Lenalidomide | 18 Years - | Celgene | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM | NCT05088330 | Newly Diagnosed... | Daratumumab | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy | NCT03993912 | Multiple Myelom... | Daratumumab SC ... Lenalidomide PO... Dexamethasone P... | 65 Years - | University Hospital, Lille | |
| A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma | NCT01698801 | Multiple Myelom... | Lenalidomide dexamethasone | 20 Years - | Celgene | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM | NCT05088330 | Newly Diagnosed... | Daratumumab | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM) | NCT05276622 | Multiple Myelom... | Comprehensive G... Qualitative pat... Surveys on well... | 55 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | NCT00378105 | Multiple Myelom... | Bortezomib Lenalidomide dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma | NCT00724568 | Multiple Myelom... | Lenalidomide Bortezomib Dexamethasone Doxil | 18 Years - | University of Michigan Rogel Cancer Center | |
| Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | NCT02155634 | Multiple Myelom... Neoplasms Plasma Cells Paraproteinemia... Blood Protein D... Hematologic Dis... Therapeutic Use... | Lenalidomide | 18 Years - | Celgene | |
| Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation | NCT06324266 | Newly Diagnosed... | Cyclophosphamid... Lenalidomide | 18 Years - 100 Years | Jinling Hospital, China | |
| A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma | NCT01698801 | Multiple Myelom... | Lenalidomide dexamethasone | 20 Years - | Celgene | |
| Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance | NCT01702831 | Multiple Myelom... | Busulfan Melphalan Lenalidomide | 18 Years - 75 Years | University Health Network, Toronto | |
| Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | NCT03733691 | Newly Diagnosed... | Ixazomib Lenalidomide | 18 Years - 100 Years | Oncotherapeutics | |
| Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma | NCT00689936 | Multiple Myelom... | Lenalidomide an... Lenalidomide pl... Melphalan, Pred... | 18 Years - | Celgene | |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | NCT04923893 | Multiple Myelom... | Bortezomib Dexamethasone Lenalidomide Cilta-cel Cyclophosphamid... Fludarabine | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | NCT00057564 | Multiple Myelom... | A (Thalidomide ... B (Placebo + De... | 18 Years - | Celgene | |
| Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | NCT04052880 | Newly Diagnosed... | Daratumumab Bortezomib Lenalidomide Dexamethasone Ixazomib | 70 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | NCT05257083 | Multiple Myelom... | Daratumumab Bortezomib Lenalidomide Dexamethasone Cilta-cel Cyclophosphamid... Fludarabine | 18 Years - | Stichting European Myeloma Network | |
| Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | NCT04052880 | Newly Diagnosed... | Daratumumab Bortezomib Lenalidomide Dexamethasone Ixazomib | 70 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | NCT00057564 | Multiple Myelom... | A (Thalidomide ... B (Placebo + De... | 18 Years - | Celgene | |
| A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | NCT00405756 | Newly Diagnosed... | Lenalidomide: D... Melphalan Prednisone Aspirin Placebo Lenalidomide: D... Lenalidomide: O... | 65 Years - | Celgene Corporation | |
| Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma | NCT03669445 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone Daratumumab | 18 Years - 65 Years | University Hospital, Toulouse | |
| Multiple Myeloma and Exercise | NCT01809717 | Newly Diagnosed... | Weight Lifting ... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma | NCT05561049 | Newly Diagnosed... | Daratumumab in ... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi) | NCT00702247 | Multiple Myelom... | Hematopoietic S... | 18 Years - 65 Years | Azienda Ospedaliera San Giovanni Battista | |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | NCT05572229 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide | 65 Years - | University Hospital, Lille | |
| Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma | NCT05561049 | Newly Diagnosed... | Daratumumab in ... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Biomarkers in Multiple Myeloma | NCT05259553 | Hematological P... Newly Diagnosed... Chemotherapy | Blood samples | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | NCT04923893 | Multiple Myelom... | Bortezomib Dexamethasone Lenalidomide Cilta-cel Cyclophosphamid... Fludarabine | 18 Years - | Janssen Research & Development, LLC | |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | NCT05572229 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide | 65 Years - | University Hospital, Lille | |
| Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | NCT03742297 | Newly Diagnosed... | Lenalidomide. Carfilzomib Bortezomib Daratumumab Dexamethasone Prednisone Melphalan | 65 Years - 80 Years | PETHEMA Foundation | |
| Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients | NCT04348006 | Newly Diagnosed... | Bortezomib 3.5 ... | 18 Years - 80 Years | Al-Rasheed University College | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients | NCT04348006 | Newly Diagnosed... | Bortezomib 3.5 ... | 18 Years - 80 Years | Al-Rasheed University College | |
| Dynamic Frailty Assessment for Guiding the Treatment in Older Adults With Newly Diagnosed Multiple Myeloma | NCT06099912 | Multiple Myelom... Frailty | 65 Years - | The First Hospital of Jilin University | ||
| Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | NCT02891811 | Multiple Myelom... | Carfilzomib Thalidomide Lenalidomide Dexamethasone | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | NCT00633542 | Multiple Myelom... | thalidomide interferon alph... | 18 Years - | Università Politecnica delle Marche | |
| Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma | NCT00689936 | Multiple Myelom... | Lenalidomide an... Lenalidomide pl... Melphalan, Pred... | 18 Years - | Celgene | |
| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | NCT04091126 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation | NCT06348147 | Newly Diagnosed... Multiple Myelom... Autologous Stem... | Daratumumab Lenalidomide Bortezomib Dexamethasone | 18 Years - | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
